Transient downmodulation of CD20 by rituximab.

被引：0
|
作者：
Jilani, I [1 ]
O'Brien, S [1 ]
Manshouri, T [1 ]
Thomas, DA [1 ]
Thomazy, VA [1 ]
Imam, M [1 ]
Naeem, S [1 ]
Verstovsek, S [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
Keating, M [1 ]
Albitar, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3174
引用
收藏
页码：804A / 804A
页数：1
相关论文
共 50 条
  • [1] Restoration of rituximab sensitivity in CD20 negative B-Cell lymphoma, cells; Epigenetic change of CD20 expression after treatment of rituximab.
    Tomita, Akihiro
    Hiraga, Junji
    Kiyoi, Hitoshi
    Kinoshita, Tomohiro
    Naoe, Tornoki
    BLOOD, 2006, 108 (11) : 155B - 155B
  • [2] Modulation of CD20 expression in B-cell lymphomas treated with rituximab.
    Seliem, RM
    Freeman, JK
    Hasserjian, RP
    BLOOD, 2002, 100 (11) : 311B - 311B
  • [3] Loss of CD20 Expression and Exhaustion of Effector Cells Limit ADCC in CLL Patients Treated with Rituximab.
    Vire, Berengere
    Perry, Justin S. A.
    Lee, Elinor
    Stennett, Lawrence S.
    Samsel, Leigh
    McCoy, Philip
    Wilson, Wyndham H.
    Bielekova, Bibiana
    Wiestner, Adrian
    BLOOD, 2009, 114 (22) : 643 - 644
  • [4] Rituximab in CD20 positive multiple myeloma
    J M Bergua
    C Cabrera
    E G Arteta
    J Prieto
    Leukemia, 2008, 22 : 1082 - 1083
  • [5] Rituximab in CD20 positive multiple myeloma
    P Moreau
    L Voillat
    L Benboukher
    C Mathiot
    C Dumontet
    N Robillard
    O Hérault
    F Garnache
    R Garand
    N Varoqueaux
    H Avet-Loiseau
    J L Harousseau
    R Bataille
    Leukemia, 2007, 21 : 835 - 836
  • [6] Rituximab in CD20 positive multiple myeloma
    Moreau, P.
    Voillat, L.
    Benboukher, L.
    Mathiot, C.
    Dumontet, C.
    Robillard, N.
    Herault, O.
    Garnache, F.
    Garand, R.
    Varoqueaux, N.
    Avet-Loiseau, H.
    Harousseau, J. L.
    Bataille, R.
    LEUKEMIA, 2007, 21 (04) : 835 - +
  • [7] Rituximab in CD20 positive multiple myeloma
    Bergua, J. M.
    Cabrera, C.
    Arteta, E. G.
    Prieto, J.
    LEUKEMIA, 2008, 22 (05) : 1082 - 1083
  • [8] Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
    Jilani, I
    O'Brien, S
    Manshuri, T
    Thomas, DA
    Thomazy, VA
    Imam, M
    Naeem, S
    Verstovsek, S
    Kantarjian, H
    Giles, F
    Keating, M
    Albitar, M
    BLOOD, 2003, 102 (10) : 3514 - 3520
  • [9] A new method of constructing CD20/CD22 bispecfic antibody fusion proteins with improved direct lymphoma cytotoxicity compared to rituximab.
    Chang, C.
    Losman, M.
    Loo, M.
    Qu, Z.
    Rossi, E. A.
    Goldenberg, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 109S - 109S
  • [10] Regarding the loss of CD20 after rituximab therapy
    Lee, R
    Braylan, RC
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (03) : 927 - 927
12345